Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
This study has been completed.
Study NCT00472290   Information provided by Amgen

First Received on May 10, 2007.   Last Updated on October 22, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hematology
MDS
Myelodysplastic Syndromes
Thrombocytopenia
Additional conditions recognized in this trial
Preleukemia
More general conditions related to this trial
Blood Platelet Disorders
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Precancerous Conditions
Interventions listed in this trial
Romiplostim (formerly AMG 531)
Sponsors listed in this trial
Amgen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services